证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2017-005 | --- | --- | --- | --- | |-----------------------|--------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------| | 投资者关系 \n活动类别 | ■ \n□ \n□ | 特定对象调研 □分析师会议 □媒体采访 \n业绩说明会 □新闻发布会 □路演活动 \n现场参观 □其他（请文字说明其他活动内容） | | | 参与单位名 | | 东方证券：左明辉 东海基金：李东升 中泰证券：赵磊 | | | 称及人员姓 名 | | | 弘尚资产：何志俊 广证恒生：冯俊曦、王静 国泰基金：姜英 | | | | 万家基金：王霄 ...

证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2020-008 | --- | --- | --- | --- | |--------------|----------------------------|-------------------------------------------|----------------------------------------------------------| | 投资者关系活 | □ | 特定对象调研 □分析师会议 □媒体采访 | | | 动类别 | □ | 业绩说明会 □新闻发布会 □路演活动 | | | | □ | 现场参观 ■其他（分析师电话会议） | | | 参与单位名称 | 共 104 家机构 138 | 名人员参与，详见附件。 | | | 及人员姓名 | | | | | 时间 | 2020 年 10 月 23 | 日 13:30-14:30；15:30-16:20 | | | 地点 | 电话会议 | | | | 上市公司接待 | | 董事会秘书：管祯玮； 财务负责人：王国其； | | | 人员 ...

证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2020-009 | --- | --- | --- | --- | |-----------------------|--------------------------|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------| | 投资者关系活 \n动类别 | ■ \n□ \n□ | 特定对象调研 □分析师会议 □媒体采访 \n业绩说明会 □新闻发布会 □路演活动 \n现场参观 □其他（分析师电话会议） | | | 参与单位名称 | | | 兴业证券：东楠、孙媛媛；长城财富资管：王政眸；蜂巢基金： | | 及人员姓名 | | | 孔宪政；招银理财：吴昆伦；东亚前海证券：孙洁玲、刘文婷； | | | | | 准锦投资：戴德舜；中庚基 ...

证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2019-005 | --- | --- | --- | --- | |-----------------------|------------------------------|------------------------------------------|--------------------------------------------------------| | | | | | | 投资者关系活 | ■ | 特定对象调研 □分析师会议 □媒体采访 | | | 动类别 | □ | 业绩说明会 □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他（请文字说明其他活动内容） | | | 参与单位名称 | | | 兴业证券：东楠；申万菱信基金：范磊；天风证券：潘海洋； | | 及人员姓名 | | | 宝盈基金：姚艺；太平资管：许希晨；广证恒生：冯俊曦； | | | | | 国盛证券：杨春雨、张金洋；国泰君安证券：丁丹、张祝源； | | | 中华保险资管：张光普。 | | | | 时间 ...

Financial Performance - In the first half of 2019, the company achieved operating revenue of 274.34 million CNY, a year-on-year increase of 25.43% [2] - The net profit attributable to shareholders was 130.48 million CNY, reflecting a growth of 25.53% compared to the same period last year [2] - The net profit excluding non-recurring gains and losses was 127.50 million CNY, up by 28.65% year-on-year [2] - The gross profit margin for the first half of 2019 was 96.96%, an increase of 2.62% from the previous year [5] Product Development - The company has several products under research, including "Artemisia annua powder drops" for adult allergic rhinitis, which is in the drug registration application stage, and the children's version is in Phase III clinical trials [3] - The "Dust Mite Skin Prick Diagnostic Kit" received approval for registration in March 2019 and is set to be officially produced and sold [4] - The company is expanding its product line with nine new skin prick products, which offer advantages such as shorter time and lower costs compared to blood tests [5] Market Expansion - The company’s sales network has expanded to most provincial cities and some county-level cities in China, with a growing patient base [3] - The allergic market has significant growth potential, with ongoing market education expected to further expand opportunities [3] Strategic Initiatives - The company has established a professional academic marketing team to enhance its coverage in the allergic disease sector and increase market influence through multi-level academic conferences [5] - The investment in Shanghai Iwu Stem Cell Technology Co., Ltd. aims to focus on anti-aging and regenerative medicine, leveraging advanced stem cell technologies [6] - Following a capital increase in January 2019, the registered capital of Iwu Stem Cell increased from 150 million CNY to 190.95 million CNY, with the company holding 78.55% of the equity [6]

证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2019-003 | --- | --- | --- | --- | |-----------------------|-------------------------|----------------------------------------------|--------------------------------------------------------| | 投资者关系活 | ■ | 特定对象调研 □分析师会议 □媒体采访 | | | 动类别 | □ | 业绩说明会 □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他（请文字说明其他活动内容） | | | 参与单位名称 | | 宝盈基金：杨思亮、李进、郝淼；方燕敏、闫梦迪 | | | 及人员姓名 | | | | | 时间 | 2019 年 6 月 25 | 日 | | | 地点 | | 浙江我武生物科技股份有限公司上海分公司会议室 | | | 上市公司接待 人员姓名 | 董事会秘书：颜华 | | | | 投资者关系活 | ...

证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2019-002 | --- | --- | --- | --- | |-----------------------|------------------------------|----------------------------------------------|--------------------------------------------------------| | | | | | | 投资者关系活 | ■ | 特定对象调研 □分析师会议 □媒体采访 | | | 动类别 | □ | 业绩说明会 □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他（请文字说明其他活动内容） | | | 参与单位名称 | 华金证券：李伟、周新明 | | | | 及人员姓名 | | | | | 时间 | 2019 年 5 月 30 日 | | | | 地点 | | 浙江我武生物科技股份有限公司上海分公司会议室 | | | 上市公司接待 人员姓名 | 董事会秘书：颜华 | | | | 投资者关系 ...

证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2018-002 | --- | --- | --- | --- | |-------------------------|----------------------------|----------------------------------------------|----------------------------------------------------------| | | | | | | 投资者关系 | ■ | 特定对象调研 □分析师会议 □媒体采访 | | | 活动类别 | □ | 业绩说明会 □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他（请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 大成基金 李博 王晶晶 | | | | 时间 | 2018 年 8 月 16 | 日上午 10:00-11:30 | | | | | | | | 地点 | | 浙江我武生物科技股份有限公司上海分公司会议室 | | | 上市公司接待 人员姓名 | 颜华 | | ...

Group 1: R&D Progress - The company is conducting clinical trials for "Artemisia annua powder drops" and "Dust mite drops" for atopic dermatitis, currently in Phase III and Phase II respectively [1] - The "Dust mite skin prick diagnostic kit" has received a notice for drug production site inspection, while "Silk protein moisturizing anti-itch dressing" is in preclinical research [2] Group 2: Financial Performance - In Q1 2018, the company achieved revenue of 106.93 million yuan, a year-on-year increase of 31.86% [2] - Net profit attributable to shareholders was 51.95 million yuan, up 35.98% from the previous year, driven by the expanding desensitization treatment market [2] Group 3: Product Usage and Costs - The treatment cost for "Dust mite drops" over a 2-year period is approximately 5,000 to 6,000 yuan [2] - The typical duration for patients using "Dust mite drops" is 2-3 years, with individual variations [2] Group 4: Market and Patient Demographics - The company’s products are primarily used in pediatrics, otolaryngology, respiratory, dermatology, and allergy departments [2] - The ratio of adult to child patients using sublingual desensitization drugs is currently indeterminate, but children generally show higher compliance [3] Group 5: Future Product Plans - "Artemisia annua powder drops" are planned for two indications: rhinitis and asthma, with adult trials preceding pediatric trials as per regulatory requirements [3] - The company is preparing for clinical trials for 9 ongoing products, with timelines for approval yet to be determined [3] Group 6: Investment and Strategic Development - The company has established Shanghai WoWu Stem Cell Technology Co., Ltd. with a registered capital of 150 million yuan and Zhejiang WoWu Stem Cell Technology Co., Ltd. with 30 million yuan, focusing on potential markets in elderly disease treatment and cell therapy [4]

证券代码：300357 证券简称：我武生物 浙江我武生物科技股份有限公司投资者关系活动记录表 编号：2018-003 | --- | --- | --- | --- | |-----------------------|--------------------------|--------------------------------------------------|----------------------------------------------------------| | 投资者关系 | ■ | 特定对象调研 □分析师会议 □媒体采访 | | | 活动类别 | □ | 业绩说明会 □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他（请文字说明其他活动内容） | | | 参与单位名 | | | 财通证券资管：朱晨 财通基金：张林飞 富邦证券：蒋栋 | | 称及人员姓 | | | 平安养老保险：叶丽 上海中域投资：袁鹏涛 晟盟资产：方一航 | | 名 | | | 上海森锦投资管理：季亮 爱建证券：章孝林 牧毅资产：乔斌 | | | | | 浦银安盛基金：陈蔚丰 上海彤源投资： ...